Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma

Annals of Surgery

Volumn 255, Issue 1, 2012, Pages 128-133

  Murali, Rajmohan ^a,b,c   Haydu, Lauren E ^b,d   Quinn, Michael J ^b,d   Saw, Robyn P M ^b,d   Shannon, Kerwin ^b,d   Spillane, Andrew J ^b,d   Stretch, Jonathan R ^b,d   Thompson, John F ^b,d   Scolyer, Richard A ^a,b,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b MELANOMA INSTITUTE AUSTRALIA   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HEAD AND NECK TUMOR; HISTOPATHOLOGY; HUMAN; LIMB; LYMPH NODE METASTASIS; LYMPHATIC DRAINAGE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MITOSIS; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; THIN PRIMARY CUTANEOUS MELANOMA; TRUNK; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84155162859     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182306c72     Document Type: Article

References (57)

1. McKinnon JG, Yu XQ, McCarthy WH, et al. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the SydneyMelanomaUnit. Cancer. 2003;98:1223-1231. (Pubitemid 37099907)
2. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging. J Clin Oncol. 2004;22:3668-3676. (Pubitemid 41095205)
3. Reintgen C, Shivers S, Reintgen M, et al. The changing face of malignant melanoma. J Surg Oncol. 2010;101:443-446.
4. Crocetti E, Caldarella A, Chiarugi A, et al. The thickness of melanomas has decreased in central Italy, but only for thin melanomas, while thick melanomas are as thick as in the past. Melanoma Res. 2010;20:422-426.
5. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
6. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634. (Pubitemid 32786275)
7. Salman SM, Rogers GS. Prognostic factors in thin cutaneous malignant melanoma. J Dermatol Surg Oncol. 1990;16:413-418. (Pubitemid 20184347)
8. Mansson-Brahme E, Carstensen J, Erhardt K, et al. Prognostic factors in thin cutaneous malignant melanoma. Cancer. 1994;73:2324-2332. (Pubitemid 24129115)
9. Kalady MF, White RR, Johnson JL, et al. Thin melanomas: predictive lethal characteristics from a 30-year clinical experience. Ann Surg. 2003;238:528-535; discussion 535-537.
10. Morton DL, Thompson JF, Cochran AJ, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med. 2006;355:1307-1317. (Pubitemid 44465459)
11. Jacobs IA, Chang CK, DasGupta TK, et al. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. Ann Surg Oncol. 2003;10:558-561. (Pubitemid 40486920)
12. Stitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or = 1.0 mm). Ann Surg Oncol. 2004;11:900-906. (Pubitemid 40486675)
13. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol. 2005;12:449-458. (Pubitemid 40884259)
14. Vaquerano J, Kraybill WG, Driscoll DL, et al. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13:198-204. (Pubitemid 43157414)
15. Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol. 2003;21:1326-1331. (Pubitemid 46606411)
16. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res. 2003;36:347-350. (Pubitemid 36442984)
17. Nahabedian MY, Tufaro AP, Manson PN. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary? Ann Plast Surg. 2003;50:601-606. (Pubitemid 36666696)
18. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg. 2008;143:892-899; discussion 899-900.
19. Lowe JB, Hurst E, Moley JF, et al. Sentinel lymph node biopsy in patients with thin melanoma. Arch Dermatol. 2003;139:617-621. (Pubitemid 36576377)
20. Wong SL, Brady MS, Busam KJ, et al. Results of sentinel lymph node biopsy in patients with thin melanoma. Ann Surg Oncol. 2006;13:302-309. (Pubitemid 43255912)
21. Vermeeren L, Van der Ent F, Sastrowijoto P, et al. Sentinel lymph node biopsy in patients with thin melanoma: occurrence of nodalmetastases and its prognostic value. Eur J Dermatol. 2010; 20:30-34.
22. Warycha MA, Zakrzewski J, Ni Q, et al. Meta-analysis of sentinel lymph node positivity in thin melanoma (
23. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. Ann Surg Oncol. 2006;13: 927-932.
24. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127: 392-399.
25. Cecchi R, Buralli L, Innocenti S, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol. 2007;34:512-515. (Pubitemid 47228525)
26. Hershko DD, Robb BW, Lowy AM, et al. Sentinel lymph node biopsy in thin melanoma patients. J Surg Oncol. 2006;93:279-285.
27. Olah J, Gyulai R, Korom I, et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol. 2003;149:662-663. (Pubitemid 37281612)
28. Kaur C, Thomas RJ, Desai N, et al. The correlation of regression in primary melanoma with sentinel lymph node status. J Clin Pathol. 2008;61:297-300. (Pubitemid 351354233)
29. Faries MB, Wanek LA, Elashoff D, et al. Predictors of occult nodal metastasis in patients with thin melanoma. Arch Surg. 2010;145:137-142.
30. Scolyer RA, Li LX, McCarthy SW, et al. Micromorphometric features of positive sentinel lymph nodes predict involvement of nonsentinel nodes in patients with melanoma. Am J Clin Pathol. 2004;122:532-539. (Pubitemid 39281249)
31. Cochran AJ, Wen DR, Huang RR, et al. Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol. 2004;17:747-755. (Pubitemid 38843356)
32. Dewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. J Clin Oncol. 2004;22:3345-3349. (Pubitemid 41103692)
33. Frankel TL, Griffith KA, Lowe L, et al. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma? Ann Surg Oncol. 2008;15:2403-2411.
34. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol. 2004;22:3677-3684. (Pubitemid 41095206)
35. McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. Ann Surg Oncol. 2002;9:137-141. (Pubitemid 34259698)
36. Page AJ, Carlson GW, Delman KA, et al. Prediction of nonsentinel lymph node involvement in patients with a positive sentinel lymph node in malignant melanoma. Am Surg. 2007;73:674-678; discussion 678-679. (Pubitemid 351396619)
37. Pearlman NW, McCarter MD, Frank M, et al. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. Am J Surg. 2006;192:878-881. (Pubitemid 44872996)
38. Reeves ME, Delgado R, Busam KJ, et al. Prediction of nonsentinel lymph node status in melanoma. Ann Surg Oncol. 2003;10:27-31.
39. Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. Ann Surg Oncol. 2008;15: 1202-1210.
40. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. J Am Coll Surg. 2005;201:37-47. (Pubitemid 40840562)
41. Salti GI, Das Gupta TK. Predicting residual lymph node basin disease in melanoma patients with sentinel lymph node metastases. Am J Surg. 2003;186:98-101. (Pubitemid 37289076)
42. Satzger I, Volker B, Meier A, et al. Criteria in sentinel lymph nodes of melanoma patients that predict involvement of nonsentinel lymph nodes. Ann Surg Oncol. 2008;15:1723-1732.
43. Starz H, Balda BR, Kramer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. Cancer. 2001;91:2110-2121. (Pubitemid 32476376)
44. Wagner JD, Gordon MS, Chuang TY, et al. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma. Cancer. 2000;89:453-462. (Pubitemid 30489897)
45. Murali R, Cochran AJ, Cook MG, et al. Interobserver reproducibility of histologic parameters of melanoma deposits in sentinel lymph nodes: implications for management of patients with melanoma. Cancer. 2009;115: 5026-5037.
46. Murali R, Desilva C, Thompson JF, et al. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28:4441-4449.
47. Lin D, Franc BL, Kashani-Sabet M, et al. Lymphatic drainage patterns of head and neck cutaneous melanoma observed on lymphoscintigraphy and sentinel lymph node biopsy. Head Neck. 2006;28:249-255. (Pubitemid 43269892)
48. Uren RF, Howman-Giles R, Thompson JF. Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med. 2003;44:570-582. (Pubitemid 39663425)
49. Paladugu RR, Yonemoto RH. Biologic behavior of thin malignant melanomas with regressive changes. Arch Surg. 1983;118:41-44. (Pubitemid 13117007)
50. Cooper PH, Wanebo HJ, Hagar RW. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance. Arch Dermatol. 1985;121:1127-1131. (Pubitemid 15018895)
51. Sondergaard K, Hou-Jensen K. Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases. Virchows Arch A Pathol Anat Histopathol. 1985;408:241-247. (Pubitemid 16174503)
52. Kang S, Barnhill RL, Mihm MC, Jr, et al. Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol. 1993;20:126-129. (Pubitemid 23215561)
53. Massi D, Franchi A, Borgognoni L, et al. Thin cutaneous malignant melanomas (< or = 1.5 mm): identification of risk factors indicative of progression. Cancer. 1999;85:1067-1076. (Pubitemid 29115585)
54. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23:8048-8056. (Pubitemid 46657407)
55. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer. 2003;97:1488-1498. (Pubitemid 36297779)
56. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol. 2004;11:426-433. (Pubitemid 40486754)
57. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol. 2007;25:1129-1134. (Pubitemid 46596766)